- Home
- VIGL vs KBSX Comparison
VIGL vs KBSX Comparison
Compare VIGL & KBSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- KBSX
- Stock Information
- Founded
- VIGL 2020
- KBSX N/A
- Country
- VIGL United States
- KBSX Taiwan
- Employees
- VIGL N/A
- KBSX N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- KBSX Recreational Games/Products/Toys
- Sector
- VIGL Health Care
- KBSX Consumer Discretionary
- Exchange
- VIGL Nasdaq
- KBSX Nasdaq
- Market Cap
- VIGL 95.2M
- KBSX 104.0M
- IPO Year
- VIGL 2022
- KBSX N/A
- Fundamental
- Price
- VIGL $2.08
- KBSX N/A
- Analyst Decision
- VIGL Strong Buy
- KBSX
- Analyst Count
- VIGL 5
- KBSX 0
- Target Price
- VIGL $19.75
- KBSX N/A
- AVG Volume (30 Days)
- VIGL 331.7K
- KBSX 67.5K
- Earning Date
- VIGL 11-07-2024
- KBSX 04-25-2025
- Dividend Yield
- VIGL N/A
- KBSX N/A
- EPS Growth
- VIGL N/A
- KBSX N/A
- EPS
- VIGL N/A
- KBSX N/A
- Revenue
- VIGL N/A
- KBSX $33,935,076.00
- Revenue This Year
- VIGL N/A
- KBSX N/A
- Revenue Next Year
- VIGL N/A
- KBSX N/A
- P/E Ratio
- VIGL N/A
- KBSX N/A
- Revenue Growth
- VIGL N/A
- KBSX N/A
- 52 Week Low
- VIGL $1.49
- KBSX $5.24
- 52 Week High
- VIGL $6.06
- KBSX $15.48
- Technical
- Relative Strength Index (RSI)
- VIGL 55.12
- KBSX N/A
- Support Level
- VIGL $1.79
- KBSX N/A
- Resistance Level
- VIGL $2.02
- KBSX N/A
- Average True Range (ATR)
- VIGL 0.16
- KBSX 0.00
- MACD
- VIGL 0.08
- KBSX 0.00
- Stochastic Oscillator
- VIGL 96.72
- KBSX 0.00
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.